Central nervous tissue degeneration promotes disease progression in multiple sclerosis (MS), and neurofilament light chain (NfL) is a validated surrogate biomarker for this process in patients with relapsing-remitting MS (RRMS) (1). The gene discussed is NEFL; the disease is myeloid sarcoma.